Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer Delivers On Biosimilars Strategy

Reports Biosimilars Sales Up By 19% To $911m In 2019

Executive Summary

Pfizer's biosimilars franchise is well on its way to becoming a blockbuster business, three years after the company launched its first US biosimilar.

You may also be interested in...



Stockwatch: Biosimilars And Dividends Connect Earnings At Pfizer And Roche

With Brexit and coronavirus depressing markets over the week, earnings season for life science companies shifted into a higher gear with a number of big companies reporting. In time, the effects of Brexit and 2019-nCoV are likely to subside, but the double-edge sword of biosimilar commercialization continues to rise from the full-year financial reports of Pfizer and Roche.

Pfizer Will Not Launch EU Adalimumab

Pfizer has announced that it does not plan to market its Amsparity adalimumab biosimilar in Europe despite it having been endorsed by the EMA in December and being in line for an imminent approval from the European Commission.

Surprise! Pfizer And Lilly File Tanezumab For Pain With FDA Despite Safety Questions

The partners have filed the first-in-class NGF inhibitor at the lower 2.5mg dose for the treatment of osteoarthritis pain, despite the drug’s challenging safety profile.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

GB149569

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel